Saturday, November 24, 2018

CBD Hemp and Cannabis Oil Producers Are Improving, Risks For Customers Remain

Image result for International Cannabis and Cannabinoids Institute (ICCI) 

[Prague, November 21, 2018] The International Cannabis and Cannabinoids Institute (ICCI) has performed the second independent test in the history of the quality of retail-available cannabinoid CBD (CBD - cannabidiol, a non-psychotropic substance in cannabis) concerning so-called CBD oils produced from technical cannabis. The results have proven the need for this independent testing (using methods accredited according to ISO 17025) and for greater public awareness.
ICCI performed the assessment in cooperation with the first European laboratory certified by the program PFC, operating at the Department of Food Analysis and Nutrition of the University of Chemistry and Technology Prague (VŠCHT).
The team led by Professor Jana Hajšlová tested 35 oils containing the non-psychotropic biologically active substance from cannabis CBD (cannabidiol) purchased in a retail store. This was the second assessment of its type. The Czech public was made aware of the results of the first assessment in April 2017. That time 29 oils were evaluated, of which only 9 have "remained" on the market. This shows the dynamic nature of the field and the interest of new investors and producers
"We were interested in the quality and authenticity of used oils and the possible content of environmental contaminants - - polycyclic aromatic hydrocarbons (PAUs), for which maximum limits have been anchored in legislation for protecting the health of their consumers. PAUs may accumulate in oils for various reasons, most frequently resulting from incorrect drying procedures due to contamination from combustion gases. It may involve components of smoke during drying - incomplete combustion products," says Professor Hajšlová explaining the key point.Pavel Kubů, managing director of ICCI, adds: "Among CBD oils, we also examined the conformity of determined contents of CBD with the producer's stated values and potential THC content (tetrahydrocannabinol - the main psychotropic substance in marijuana).''
Mainly an excessive THC content in the blood after using CBD oils represents unexpected risks for customers all too often. THC is another medicinally active substance from cannabis, but it is psychoactive as opposed to CBD. Even relatively low amounts can cause changes in perception among more sensitive individuals, and that can threaten their capacity to drive and make decisions in general - especially in case of being unaware of the possibilities of having one's psyche influenced by an external substance. Another problem may be drivers testing positive for THC during traffic stops, which can lead at the very least to losing one's driving privileges at least temporarily. Generally speaking: any psychoactive substance unknowingly present in one's body is always a problem.
It is therefore important for customers to be informed accurately and truthfully about THC content right on the product packaging. "People don't know that they have in their bodies a strictly controlled substance, and may, therefore, run into problems not only during traffic accidents but also in employment relationships," emphasizes Pavel Kubu.
Of the 35 tested samples, 9 had a THC level involving risk. For correct labeling on packaging, the situation was more complicated: Ten samples fulfilled requirements concerning THC content. Thirty samples fulfilled requirements concerning CBD content.
Of 9 samples that passed the previous assessment, originally 4 did not fulfill the CBD declaration. After consulting with ICCI, they all made improvements. This shows the importance of not only independent testing but also of the consequent education of producers.
As opposed to the previous assessment, the current interpretation of EFSA was applied - i.e. how much THC can a person take daily without risk. Twenty samples were in compliance with the limit of 1 microgram per kilogram of body weight.
ICCI innovation director Steph Sherer underscored the importance of complex assessment so that products would comply with qualitative demands for the given category of products.
"ICCI is not a regulator. We offer public data and information; we are concerned with providing consumers with a service and with their safety. We meanwhile care about increasing the quality of the offer on the part of the cannabis industry, which has grown dramatically in recent years across the globe. We are contacting all manufacturers of tested products, we share the results and we offer help when checking the safety and increasing the quality of the product. The list of these products that satisfied limits valid for dietary supplements will be available to all consumers at the Website PFC International. Information will be provided to members of patient organizations associated in the international association IMCPC by means of the society KOPAC regarding the quality of a specific oil they are using. They will find out whether it was among those tested, and if so, with what results," adds Steph Sherer.

Also available at the same address will be the summarized, more detailed results of how the analyzed products comply with the declared quality.

ICCI (International Cannabis and Cannabinoids Institute) was established as a common project of patient organizations, Czech scientific societies and the American investment firm Dioscorides Global Holdings. It is headquartered in Prague, and as a so-called center of excellence, it cooperates for example with the University of Chemistry and Technology Prague, Charles University, Czech Technical University, the Czech University of Life Sciences in Prague, Masaryk University in Brno, Mendel University in Brno, Palacký University in Olomouc and Hebrew University in Jerusalem.
PFC (Patient Focused Certification) is an independent program for certification of the quality of cannabis-based products designed for consumption either as pharmaceuticals, medical devices, food supplements, food or cosmetics.
The Patient Focused Certification (PFC) program offers a variety of services designed to prepare businesses for excellence in the medical cannabis industry. PFC is what patients, healthcare providers, companies, and regulators can depend on to identify reliable, high-quality medical cannabis, businesses, products, and services. PFC offers company certification, consultation services, and industry training for any business regardless of its stage of development or role in the supply chain.
PFC was developed by Americans for Safe Access using the Cannabis Monograph created with the American Herbal Products Association (AHPA)  and the American Herbal Pharmacopoeia (AHP). These standards have been directly adopted by nearly half the medical cannabis programs in the US. PFC business certification and professional training are available in all medical cannabis states including the District of Columbia. PFC can help you no matter which state you are in, what you do, or what stage your business is in.

ÚAPV (Department of Food Analysis and Nutrition), a part of the Faculty of Food and Biochemical Technology of the University of Chemistry and Technology Prague, has the best equipment available, and its implemented tests are accredited according to ISO 17025. Research projects mainly focus on the issue of quality, authenticity and chemical safety of foods, feeds, food raw materials, dietary supplements, etc. In recent years, in the framework of interdisciplinary research, so-called "omics" technologies have been applied when assessing in vivo/in vitro effects evoked by biologically active substances (both beneficial and toxic). Interdisciplinary cooperation involves a series of medical institutions.

Photographic documentation of oils meeting all tested parameters: Download Powerpoint
CBD oils, the second series of test samples: Download PDF
CBD oils, comparing identical samples from both test series: Download PDF

More information:
Prof. Ing. Jana Hajšlová CSc.,
Ing. Marie Fenclová,
Jakub Večerka, 603 185 441,